DGIdb - PAROXETINE Drug Record

PAROXETINE chembl:CHEMBL490 Approved

Alternate Names:

PEXEVA
PAXIL
BRL-29060
PAROXETINE
PAXIL [AS HYDROCHLORIDE]
(−)-(3S,4R)-4-(P-FLUOROPHENYL)-3-((3,4-(METHYLENEDIOXY)PHENOXY)METHYL)PIPERIDINE
(3S-TRANS)-3-((1,3-BENZODIOXOL-5-YLOXY)METHYL)-4-(4-FLUOROPHENYL)PIPERIDINE
PAROXETINUM
(-)-(3S,4R)-4-(P-FLUOROPHENYL)-3-((3,4-(METHYLENEDIOXY)PHENOXY)METHYL)PIPERIDINE
PAROXETINA
pubchem.compound:43815
chembl:CHEMBL490
drugbank:00715
chemidplus:61869-08-7
rxcui:32937

Drug Info:

FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antidepressant
Drug Class	antidepressive agents, second-generation
Year of Approval	1992

(3 More Sources)

Publications:

Murata Y et al., 2010, Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome., J Clin Psychopharmacol
Sugai T et al., 2006, The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine., Pharmacogenomics J
Bixo et al., 2001, Binding of [3H]paroxetine to serotonin uptake sites and of [3H]lysergic acid diethylamide to 5-HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment., Psychoneuroendocrinology
Meyer et al., 2001, The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study., Am J Psychiatry
Kato M et al., 2009, 5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients., Psychiatry Res
Wilkie MJ et al., 2009, Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy., Pharmacogenomics J
Tanaka M et al., 2008, Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea., Int J Neuropsychopharmacol
Murphy GM Jr et al., 2003, Pharmacogenetics of antidepressant medication intolerance., Am J Psychiatry
Foster RH et al., 1997, Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder., CNS Drugs
Newcombe F et al., 1969, Alkaloids of the leaves of Voacanga schweinfurthii Stapf., Planta Med
Yang Z et al., 2012, Association of APC and REEP5 gene polymorphisms with major depression disorder and treatment response to antidepressants in a Han Chinese population., Gen Hosp Psychiatry
Kurose K et al., 2012, Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression., Psychiatry Res
Breitenstein B et al., 2016, Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study., J Psychiatr Res
Huang X et al., 2013, ABCB6, ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patients., Pharmacogenomics
de Klerk OL et al., 2013, ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder., Pharmacogenomics J
Perroud N et al., 2011, Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample., Pharmacogenomics
Uhr M et al., 2008, Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression., Neuron
Wang XC et al., 2014, Association of 2 neurotrophic factor polymorphisms with efficacy of paroxetine in patients with major depressive disorder in a Chinese population., Ther Drug Monit
Benedetti F et al., 2009, The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting., Psychopharmacology (Berl)
Niitsu T et al., 2013, Pharmacogenetics in major depression: a comprehensive meta-analysis., Prog Neuropsychopharmacol Biol Psychiatry
Zou YF et al., 2010, Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders., Neurosci Lett
Sarginson JE et al., 2010, FKBP5 polymorphisms and antidepressant response in geriatric depression., Am J Med Genet B Neuropsychiatr Genet
Kirchheiner J et al., 2008, Genetic variants in FKBP5 affecting response to antidepressant drug treatment., Pharmacogenomics
Papiol S et al., 2007, Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment., J Affect Disord
Binder EB et al., 2004, Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment., Nat Genet
Ishiguro S et al., 2011, Determinants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorder., Eur J Clin Pharmacol
Yevtushenko OO et al., 2010, Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism., J Affect Disord
Illi A et al., 2009, 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression., Neuroreport
Kato M et al., 2009, Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder., Am J Med Genet B Neuropsychiatr Genet
Baune BT et al., 2008, Serotonin receptor 1A-1019C/G variant: impact on antidepressant pharmacoresponse in melancholic depression?, Neurosci Lett
Drago A et al., 2008, 5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies., Int J Neuropsychopharmacol
Glubb DM et al., 2010, Association of a functional polymorphism in the adrenomedullin gene (ADM) with response to paroxetine., Pharmacogenomics J
Wang P et al., 2018, Association of DNA methylation in BDNF with escitalopram treatment response in depressed Chinese Han patients., Eur J Clin Pharmacol
Murphy GM Jr et al., 2013, BDNF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression., Pharmacogenet Genomics
Musil R et al., 2013, No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression., Eur Arch Psychiatry Clin Neurosci
Yoshimura R et al., 2011, The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients., Prog Neuropsychopharmacol Biol Psychiatry
Zou YF et al., 2010, Association of brain-derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients., Neuropsychobiology
Domschke K et al., 2010, Brain-derived neurotrophic factor ( BDNF) gene: no major impact on antidepressant treatment response., Int J Neuropsychopharmacol
Arias B et al., 2013, TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression., Neuropsychobiology
Dobrinas M et al., 2011, Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility., Clin Pharmacol Ther
Lin KM et al., 2010, CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine., Pharmacogenomics
Preuss et al., 2000, Serotonin transporter gene regulatory region polymorphism (5-HTTLPR), [3H]paroxetine binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity., Psychiatry Res
Tatsumi et al., 1997, Pharmacological profile of antidepressants and related compounds at human monoamine transporters., Eur. J. Pharmacol.
Scholze et al., 2000, Transporter-mediated release: a superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter., J. Pharmacol. Exp. Ther.
Wihlbäck et al., 2001, Influence of postmenopausal hormone replacement therapy on platelet serotonin uptake site and serotonin 2A receptor binding., Obstet Gynecol
Pollock et al., 2000, Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression., Neuropsychopharmacology
Haughey et al., 2000, The effects of methamphetamine on serotonin transporter activity: role of dopamine and hyperthermia., J. Neurochem.
Davis BA et al., 2016, Mechanism of Paroxetine (Paxil) Inhibition of the Serotonin Transporter., Sci Rep
Tsuchimine S et al., 2012, DRD3, but not BDNF, genotype affects treatment response to paroxetine in major depressive disorder: a preliminary study., J Clin Psychopharmacol

PAROXETINE FKBP5

Interaction Score: 1.72

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23733030 21449676 20709156 19676097 18597649 17467808 15565110

Sources:
PharmGKB
PAROXETINE MDGA2

Interaction Score: 1.72

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22445761

Sources:
PharmGKB
PAROXETINE REEP5

Interaction Score: 1.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22795047

Sources:
PharmGKB
PAROXETINE SRP19

Interaction Score: 1.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22795047

Sources:
PharmGKB
PAROXETINE TPH1

Interaction Score: 1.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23733030 23221997 19590397

Sources:
PharmGKB
PAROXETINE GDNF

Interaction Score: 0.86

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24577123

Sources:
PharmGKB
PAROXETINE ADM

Interaction Score: 0.74

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19636336

Sources:
PharmGKB
PAROXETINE HTR3B

Interaction Score: 0.64

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20075642 16534507

Sources:
PharmGKB
PAROXETINE SLC6A4

Interaction Score: 0.5

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name CRx-139

Novel drug target Established target

Trial Name paroxetine hydrochloride,Paxil, Seroxat

PMIDs:
10980326 9537821 10869387 11530128 11027924 10987842 27032980 23338224

Sources:
TdgClinicalTrial TEND
PAROXETINE HTR1A

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23733030 21688171 19800133 19590397 18484082 18387740 18047755

Sources:
PharmGKB
PAROXETINE BDNF

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29748862 23733030 23619509 22965830 21338649 20016225 19236730

Sources:
PharmGKB
PAROXETINE HTR2A

Interaction Score: 0.23

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

PMIDs:
11403977 11136637 19361869 18253134 17697394 14514498 23338224 5821956

Sources:
PharmGKB
PAROXETINE COMT

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18989660

Sources:
PharmGKB
PAROXETINE HTR1B

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21449676

Sources:
PharmGKB
PAROXETINE DRD3

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22926616

Sources:
PharmGKB
PAROXETINE ABCB1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26704739 24192121 22641028 21449676 18215618

Sources:
PharmGKB
PAROXETINE CYP3A5

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PAROXETINE MTOR

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PAROXETINE CYP1A2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21593735 21121774

Sources:
PharmGKB
PAROXETINE ATXN2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PAROXETINE CYP2D6

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
FDA
PAROXETINE AR

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PAROXETINE EHMT2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PAROXETINE CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB

TEND: PAROXETINE
- Version: 01-August-2011
Alternate Names:

PAROXETINE Primary Drug Name

Drug Info:

Year of Approval 1992

Drug Class antidepressive agents, second-generation

Publications:
TdgClinicalTrial: PAROXETINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antidepressant

Drug Class Small Molecule

FDA Approval approved

Publications:

PharmGKB: paroxetine

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Murata Y et al., 2010, Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome., J Clin Psychopharmacol

Sugai T et al., 2006, The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine., Pharmacogenomics J

Kurose K et al., 2012, Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression., Psychiatry Res

TTD: Paroxetine
- Version: 2020.06.01
Alternate Names:

D06GDY TTD Drug ID

Drug Info:

Publications:
DTC: PAROXETINE
- Version: 02-September-2020
Alternate Names:

CHEMBL490 ChEMBL Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL490
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
FDA: Paroxetine
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Trial Name	CRx-139
Novel drug target	Established target
Trial Name	paroxetine hydrochloride,Paxil, Seroxat

PAROXETINE Drug Record

PAROXETINE chembl:CHEMBL490 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23733030 21449676 20709156 19676097 18597649 17467808 15565110

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22445761

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22795047

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22795047

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23733030 23221997 19590397

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24577123

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19636336

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20075642 16534507

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name CRx-139 Novel drug target Established target Trial Name paroxetine hydrochloride,Paxil, Seroxat

PMIDs: 10980326 9537821 10869387 11530128 11027924 10987842 27032980 23338224

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23733030 21688171 19800133 19590397 18484082 18387740 18047755

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29748862 23733030 23619509 22965830 21338649 20016225 19236730

Sources: PharmGKB

Interaction Types & Directionality: agonist (activating)

Interaction Info:

PMIDs: 11403977 11136637 19361869 18253134 17697394 14514498 23338224 5821956

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18989660

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21449676

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22926616

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26704739 24192121 22641028 21449676 18215618

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21593735 21121774

Interaction Types & Directionality:

n/a

PMIDs:
23733030 21449676 20709156 19676097 18597649 17467808 15565110

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22445761

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22795047

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22795047

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23733030 23221997 19590397

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24577123

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
19636336

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20075642 16534507

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name CRx-139

Novel drug target Established target

Trial Name paroxetine hydrochloride,Paxil, Seroxat

PMIDs:
10980326 9537821 10869387 11530128 11027924 10987842 27032980 23338224

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

n/a

PMIDs:
23733030 21688171 19800133 19590397 18484082 18387740 18047755

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29748862 23733030 23619509 22965830 21338649 20016225 19236730

Sources:
PharmGKB

Interaction Types & Directionality:

agonist (activating)

PMIDs:
11403977 11136637 19361869 18253134 17697394 14514498 23338224 5821956

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18989660

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
21449676

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22926616

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26704739 24192121 22641028 21449676 18215618

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
21593735 21121774

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
FDA

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Alternate Names:

PAROXETINE Primary Drug Name

Drug Info:

Year of Approval 1992

Drug Class antidepressive agents, second-generation

Drug Info:

Drug Indications antidepressant

Drug Class Small Molecule

FDA Approval approved

Alternate Names:

D06GDY TTD Drug ID

Alternate Names:

CHEMBL490 ChEMBL Drug ID